|1.||Waters, R: 2 articles (12/2012 - 01/2007)|
|2.||Protopapa, Carmelo: 2 articles (12/2003 - 07/2002)|
|3.||Lee, Sun Bin: 1 article (05/2015)|
|4.||Chang, Chul: 1 article (05/2015)|
|5.||Nadarajah, Jeya T: 1 article (12/2012)|
|6.||Erel, E: 1 article (12/2012)|
|7.||Walmsley, Sharon: 1 article (12/2012)|
|8.||Raboud, Janet: 1 article (12/2012)|
|9.||Su, DeSheng: 1 article (12/2012)|
|10.||Loutfy, Mona R: 1 article (12/2012)|
09/01/2009 - "Seven studies were documented in the medical literature that examined the safety of Bio-alcamid (Polymekon, Brindisy, Italy); all reported no cases of tissue migration, foreign body granulomas, allergenicity, or interference with the control of cell proliferation. "
10/01/2008 - "They include: switching from thymidine analogues to tenofovir or abacavir in lipoatrophy, or switching from protease inhibitors associated with hyperlipidaemia to a protease-sparing option; injection into the face with either biodegradable fillers such as poly-L-lactic acid and hyaluronic acid (a temporary measure requiring re-treatment) or permanent fillers such as bio-alcamid (with the risk of foreign body reaction or granuloma formation); and structured treatment interruption with the risk of loss of virological control and disease progression. "
12/01/2012 - "Among patients with infections, the median time from first Bio-Alcamid treatment to infection was 32 months (interquartile range, 21-42). "
09/01/2009 - "To review our experience with the long-term orbitofacial complications of polyalkylimide 4% (Bio-Alcamid), including migration, infection, and recurrent swelling. "
09/01/2006 - "[Delayed infection after Bio-alcamid implantation]."
12/01/2012 - "Potential risk factors for infection include severity of FLA and a preceding history of facial manipulation, including Bio-Alcamid touch-up treatments, cosmetic surgery, facial trauma, and dental work. "
05/01/2015 - "To address this problem, we reviewed the safety of long-acting fillers on the basis of a rare case of surgical incision and drainage of a nasal septal abscess that developed in a patient 2 years after Bio-Alcamid was injected into the nasal region."
09/01/2010 - "Late-onset gluteal Escherichia coli abscess formation 7 years after soft tissue augmentation with Bio-Alcamid in a HIV-positive patient."
07/01/2007 - "Late-onset facial abscess formation after cosmetic soft tissue augmentation with bio-alcamid."
|2.||Protease Inhibitors (Protease Inhibitor)
|3.||Hyaluronic Acid (Hyaluronan)
|7.||poly(lactic acid) (polylactic acid)
|1.||Free Tissue Flaps